MedTrace Logo

Prostate Cancer Patients With Biochemical Recurrence

NCT03527199 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2023-04-11

No results posted yet for this study

Summary

Evaluation of detection rate of 18F-Fluciclovine compared to current standard of care imaging techniques within 30 days of the standard of care imaging study and a 6 month phone follow-up

Conditions

  • Patients With Prostate Cancer

Interventions

DIAGNOSTIC_TEST

Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)

Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • Medhat Osman

    lead FED

Principal Investigators

  • Medhat M Osman, MD,PhD · St. Louis VA Helathcare System

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2023-04-10
Completion
2023-04-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03527199 on ClinicalTrials.gov